Canagliflozin : A New Hope in the Antidiabetic Armamentarium

Author(s): Vasiliki K. Katsi, Christos A. Michalakeas, Charalambos E. Grassos, Georgia D. Vamvakou, John P. Lekakis, Dimitris Tousoulis, Christodoulos I. Stefanadis, Thomas K. Makris, Ioannis E. Kallikazaros.

Journal Name: Recent Patents on Cardiovascular Drug Discovery (Discontinued)

Volume 8 , Issue 3 , 2013


Canagliflozin-with the patent number WO2011142478A1- belongs to a novel class of antidiabetic drugs known as SGLT2 inhibitors, which has been approved by FDA in March 2013. This medication acts through the inhibition of glucose reabsorption in the kidney resulting in glucosuria and thus lowering of glucose blood levels. There are several phase III clinical ongoing trials involving this new class of medications. So far promising results have been shown. This review article summarizes current knowledge regarding the novel SGLT2 inhibitor canagliflozin and its future perspectives in the treatment of type 2 diabetes mellitus.

Keywords: Anti-diabetics, canagliflozin, hyperglycemia, invokana, sodium-glucose cotransporter-2 (SGLT2) inhibitors, type 2 diabetes mellitus.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [216 - 220]
Pages: 5
DOI: 10.2174/1574890108666131213100613
Price: $100

Article Metrics

PDF: 15